145918-75-8

Usage

Uses

Used in Anticancer Applications:
TROXACITABINE is used as an anticancer agent for patients with refractory lymphoproliferative diseases. It works by incorporating itself into the DNA of cancer cells, thereby inhibiting their replication and ultimately leading to cell death. This makes it a valuable tool in the fight against cancer, particularly for patients who do not respond well to traditional chemotherapy treatments.

InChI:InChI=1/C8H11N3O4/c9-5-1-2-11(8(13)10-5)6-4-14-7(3-12)15-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6?,7-/m0/s1

Upstream product

• 146996-25-0 (-)-(2S,4S)-N⁴-benzoyl-1-<2-<(benzoyloxy)methyl>-1,3-dioxolan-4-yl>cytosine 
• 192581-99-0 (2S)-2-((benzyloxy)methyl)-1,3-dioxolan-4-yl acetate 
• 145875-99-6 ((2S)-4-acetoxy-1,3-dioxolan-2-yl)methyl acetate 
• 145414-63-7 Benzoic acid (2S,4S)-4-(4-acetylamino-2-oxo-2H-pyrimidin-1-yl)-[1,3]dioxolan-2-ylmethyl ester 

Relevant academic research and scientific papers

MIV-818/LENVATINIB COMBINATION THERAPY FOR LIVER CANCER

Use of lenvatinib, or a pharmaceutically acceptable salt thereof in combination with a compound of the formula MIV-818: (MIV-818) or pharmaceutically acceptable salt thereof, in the treatment of liver cancer or liver metastases. The respective dosage regimes of the compounds can be delivered concurrently or alternately.

Troxacitabine synthesis and crystalline forms

The present invention provides a troxacitabine synthesis method and troxacitabine crystallization methods. Further, the present invention also provides troxacitabine crystalline forms and application.

DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER

The invention provides compounds of formula (I), wherein: R1 is OR11, or NR5R5'; R2 is H or F; R5 is H, C1-C6alkyl, OH, C(=O)R6, O(C=O)R6 or O(C=O)OR6; R5′ is H or C1-C6alkyl; R6 is C1-C6alkyl or C3-C7cycloalkyl; R13 is H, phenyl, pyridyl, benzyl, indolyl or naphthyl wherein the phenyl, pyridyl, benzyl, indolyl and naphthyl is optionally substituted with 1, 2 or 3 R22; and the other variables are as defined in the claims, which are of use in the treatment of cancer, and related aspects.

Structure-activity relationships among a new class of antiviral heterosubstituted 2',3'-dideoxynucleoside analogues

3'-Oxa-4'-thiocytidine nucleoside analogues 14-17 were prepared from oxathiolanes 10 and 11, and evaluated for activity against HIV-1 and HBV in vitro. The nucleoside analogues were found to possess potent activities against HIV-1 in a panel of cell lines. Compound 16 is moderately active against HBV in 2.2.15 cells.

L-β-(2S,4S)- and L-α-(2S,4R)-dioxolanyl nucleosides as potential anti- HIV agents: Asymmetric synthesis and structure-activity relationships

In order to study the structure-activity relationships of L-(2S,4S)- and L-(2S,4R)-dioxolanyl nucleosides as potential anti-HIV agents, various enantiomerically pure L-(2S,4S)- and (2S,4R)-dioxolanylpyrimidine and - purine nucleosides have been synthesize

Oxidative Degradation of L-Ascorbic Acid Acetals to 2',3'-Dideoxy-3'-Oxaribofuranosides. Synthesis of Enantiomerically Pure 2',3'-Dideoxy-3'-Oxacytidine Stereoisomers as Potential Antiviral Agents

Enantiomerically pure 2',3'-dideoxy-3'-oxacytidine nucleoside analogues were synthesized from L-ascorbic acid in eight steps and good overall yield.

Potent Anti-HIV and Anti-HBV Activities of (-)-L-&β-Dioxolane-C and (+)-L-&β-Dioxolane-T and Their Asymmetric Syntheses.

The asymmetric syntheses of (+)-L-β-dioxolane-T and (-)-L-β-dioxolane-C were accomplished starting from 1,6-anhydro-L-β-gulopyranose, and their anti-HIV and anti-HBV activities were evaluated in human PBM cells, CEM cells and 2.2.15 cells, respectively. K